论文部分内容阅读
采用高效液相色谱法（ＨＰＬＣ）测定盐酸环丙沙星的血药浓度。色谱条件为：紫外检测波长λ２７７ｎｍ；分析柱为ＨＰ－ＲＰ－ＯＤＳＣ１８柱，Φ４．６×２２０ｍｍ；流动相：乙腈∶（溴化四丁基铵０．００８ｍｏｌ·Ｌ－１＋磷酸二氢钾水溶液０．０１１ｍｏｌ·Ｌ－１）＝１４∶８６，配好后磷酸调ｐＨ至２．７４±０．０２。本法血清最低检出浓度０．０１μｇ·ｍｌ－１。对１０名受试者口服５００ｍｇ两种盐酸环丙沙星片后进行药动学和生物利用度研究。药－时曲线经拟合为二室开放模型，其Ｔ１／２β分别为４．６８±０．５３ｈ与４．４０±０．４７ｈ，Ｔｍａｘ分别为１．２８±０．０７ｈ与１．３３±０．０７ｈ，Ｃｍａｘ分别为６．４４±０．６１（μｇ·ｍｌ－１）与５．８８±０．４０（μｇ·ｍｌ－１），ＡＵＣ分别为１９．８８±１．８３（μｇ·ｈ－１·ｍｌ－１）和１９．２４±１．０８（μｇ·ｈ－１·ｍｌ－１）。供试品片剂的相对生物利用度为１０３．３２±４．８１％（９９．５８±４．６３％，经含量校正），经统计分析两种制剂具有生物等效性。
The plasma concentrations of ciprofloxacin hydrochloride were determined by high performance liquid chromatography (HPLC). The chromatographic conditions were: UV detection wavelength λ277nm; analytical column HP-RP-ODSC18 column, Φ4.6 × 220mm; mobile phase: acetonitrile: tetrabutyl ammonium bromide 0.008mol·L-1 + .011mol·L-1) = 14:86, with a good pH adjusted to pH 2.74 ± 0.02. The minimum detectable serum concentration of 0.01μg · ml-1. Pharmacokinetics and bioavailability of two ciprofloxacin hydrochloride tablets (500 mg) were orally administered to 10 subjects. The drug-time curve was fitted to a two-compartment open model with T1 / 2β of 4.68 ± 0.53h and 4.40 ± 0.47h, Tmax of 1.28 ± 0.07h and 1.33 ± 0.07h, Cmax were 6.44 ± 0.61 (μg · ml-1) and 5.88 ± 0.40 (μg · ml-1) respectively, AUC were 19.88 ± 1.83 h-1 · ml-1) and 19.24 ± 1.08 (μg · h-1 · ml-1). The relative bioavailability of the tested tablets was 103.32 ± 4.81% (99.58 ± 4.63%, corrected by content), and the bioavailability of the two preparations was statistically analyzed.